Physician profile
Brittney E Owen
NPI 1184092579
$2,013.97
in general payments reported to CMS, 2019-2025
31 companies · $19.99 in 2025
The $19.99 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,269 · 2022: $239 · 2023: $451 · 2024: $35.44 · 2025: $19.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $506.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $582.40 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $163.12 | 2021-2023 | Breztri |
| Astellas Pharma US INC | $146.46 | 2021-2023 | Myrbetriq, Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $114.13 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $102.27 | 2021-2023 | Rexulti |
| Antares Pharma, INC. | $96.76 | 2021-2022 | |
| Lilly USA, LLC | $76.38 | 2021 | |
| Esperion Therapeutics, INC. | $72.90 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.59 | 2021 | |
| Amgen INC. | $51.33 | 2021-2023 | Otezla, Repatha |
| Clarus Therapeutics INC. | $44.05 | 2021 | |
| Itamar Medical INC | $43.96 | 2023 | Watchpatone |
| Alkermes, INC. | $42.57 | 2021-2023 | Vivitrol |
| Novo Nordisk INC | $36.01 | 2021 | |
| Sanofi-Aventis U.S. LLC | $34.53 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $32.70 | 2022 | |
| Amarin Pharma, INC. | $31.05 | 2021 | |
| Pfizer INC. | $30.84 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $30.02 | 2021 | |
| Ironwood Pharmaceuticals, INC | $28.29 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.06 | 2022 | |
| Orexo US, INC. | $20.13 | 2024 | Zubsolv |
| Genentech USA, INC. | $19.80 | 2021 | |
| Sunovion Pharmaceuticals INC. | $18.88 | 2021 | |
| Insulet Corporation | $17.75 | 2021 | |
| Lundbeck LLC | $17.08 | 2021 | |
| Collegium Pharmaceutical, INC. | $15.79 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.77 | 2022 | |
| Indivior INC. | $13.22 | 2021 | |
| Avion Pharmaceuticals | $12.99 | 2021 | |
| Glaxosmithkline, LLC. | $12.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittney Owen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.